gavilimomab
chemical compound
≈ 1 min read
Names in other languages
- العربيةغافيليموماب
- Englishgavilimomab
- Françaisgavilimomab
- ItalianoGavilimomab
- NederlandsGavilimomab
- Tiếng ViệtGavilimomab
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147. Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy. It was originally developed by Abgenix, which was later acquired by Amgen.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1177181286 under CC BY-SA 4.0; modifications have been made.